Results 141 to 150 of about 50,472 (297)

Identification and Phylogenetic Characterisation of Novel Adeno‐Associated Virus Capsids in Non‐Human Primate Tissues

Cell Proliferation, Volume 59, Issue 5, May 2026.
AAV's widespread application is currently confronting critical challenges. This study established a systematic framework of ‘natural discovery–evolutionary analysis–functional optimization’, providing a new paradigm for the development of next‐generation AAV vectors with clinical‐grade tissue specificity, low immunogenicity, and cross‐species ...
Liyu Zhu, Kai Xu, Yali Ding, Kailun Liu, Jing Liu, Zongren Hou, Rui Niu, Ning Yang, Hualing Qin, Baoyang Hu, Ying Zhang, Wei Li   +11 more
wiley   +1 more source

Editorial: Stereotactic body radiotherapy for lung cancer

Frontiers in Oncology, 2023
An Liu, Stephanie G. C. Kroeze
doaj   +1 more source

Online adaptive radiotherapy in stereotactic body radiotherapy for pancreatic cancer patients

Scientific Reports
Stereotactic radiation therapy (SBRT) has emerged as a promising treatment modality for locally advanced pancreatic cancer. The aim of this study is to assess the dosimetric efficacy of online adaptive radiotherapy (ART) in comparison to image-guided ...
Dazhen Jiang, Jin Peng, Hui Xu, Dajiang Wang, Conghua Xie, Xiaoyong Wang, Fuxiang Zhou, Hui Liu   +7 more
doaj   +1 more source

PO-0652: Stereotactic body radiotherapy for metastatic lung tumors with emphasis on the difference in oligometastatic state

, 2015
Takayoshi Yamamoto, Yuzuru Niibe, Hironobu Yamashita, Kuniaki Katsui, K. Nakagawa, S. Kanazawa, Jiro Kawamori, Masashi Koto, Atsuro Terahara, K. Jingu   +9 more
openalex   +1 more source

Durvalumab–Tremelimumab in Advanced Hepatocellular Carcinoma: Real‐World Data From the LOR‐HCC (Lombardy Real‐World HCC Group)

Liver International, Volume 46, Issue 5, May 2026.
ABSTRACT Background and Aim Dual immune checkpoint blockade with tremelimumab plus durvalumab (STRIDE) is an established first‐line therapy for unresectable hepatocellular carcinoma (uHCC); however, real‐world evidence on its safety, toxicity kinetics and liver function dynamics remains limited.
Andrea Casadei‐Gardini, Lorenzo Canova, Federica Tosi, Silvia Camera, Elisa Bocchero, Pietro Pozzoni, Martina Torchio, Salvatore Corallo, Daniela Costantino, Annamaria Stagno, Giulia Grizzi, Rita Gengarle, Gianluca Tomasello, Nasim Ansarin, Mariangela Bruccoleri, Katia Bencardino, Mara Persano, Martina Pino, Alessia Riva, Sara Vavassori, Lorenzo Argiento, Chiara Mazzarelli, Massimo De Giorgio, Elena Rota Caremoli, Margherita Rimini, Tiziana Pressiani, Lorenza Rimassa, Massimo Iavarone   +27 more
wiley   +1 more source

Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen [PDF]

, 2018
Bradley, Jeffrey, Curcuru, Austen, DeWees, Todd, Green, Olga, Henke, Lauren, Kashani, Rojano, Michalski, Jeff, Mutic, Sasa, Olsen, Jeffrey, Parikh, Parag, Robinson, Clifford   +10 more
core   +2 more sources

Assessment of the Advancement of Alveolar Bone Loss in Canine Patients Receiving Definitive Radiotherapy for Sinonasal Tumors

Veterinary Radiology &Ultrasound, Volume 67, Issue 3, May 2026.
ABSTRACT Radiotherapy for the treatment of sinonasal tumors in dogs is generally well tolerated, but the range of long‐term adverse effects remains poorly understood. In people receiving radiation for head and neck tumors, existing dental disease is a predisposing factor for radiation‐induced oral complications that can lead to worsening periodontal ...
Erin Paul‐Stewart, Kekauilani Zukeran‐Kerr, Alex Pinto, Christopher Snyder, Nate Van Asselt   +4 more
wiley   +1 more source

Dose escalation of Stereotactic Body Radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer patients with CyberKnife: protocol of a phase I study [PDF]

, 2017
Shuiwang Qing, Xiaoping Ju, Yangsen Cao, Huojun Zhang   +3 more
openalex   +1 more source

Three discipline collaborative radiation therapy (3DCRT) special debate: Equipment development is stifling innovation in radiation oncology [PDF]

, 2011
Kim, Leonard, Markovina, Stephanie, Van Nest, Samantha J, Eisaman, Subarna, Santanam, Lakshmi, Sullivan, Julie M, Dominello, Michael, Joiner, Michael C, Burmeister, Jay   +8 more
core   +3 more sources

NIVORAD: A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy.

, 2017
Paul Mitchell, Shankar Siva, Peey‐Sei Kok, Kenneth J. O’Byrne, Annie Yeung, Ann Livingstone, Mark W. Donoghoe, Sonia Yip, Martin R. Stockler, Australasian Lung Cancer Trials Group (ALTG)   +9 more
openalex   +2 more sources